Fujirebio Diagnostics, Inc., a subsidiary of global diagnostics company Fujirebio Holdings, has acquired all shares of Plasma Services Group, Inc., a specialized supplier of rare biological materials for the in vitro diagnostics (IVD) and life science industries. The transaction value was not disclosed.
The acquisition positions Fujirebio to strengthen its role as a trusted contract development and manufacturing organization (CDMO) partner by expanding access to critical biological raw materials that are often difficult to obtain. Founded in 2004, Plasma Services Group has built a reputation for collecting, screening, and supplying high-quality rare biological materials essential for research and development and manufacturing in the diagnostics sector.
Strategic Focus on Rare Disease Materials
Plasma Services Group operates from a state-of-the-art FDA-registered, ISO-certified facility in Moorestown, New Jersey, where it provides sera and other samples for control reagents and calibrators across a wide range of diseases. The company has developed particular expertise in the field of rare diseases, offering sample collection services on a global scale.
"We are excited to welcome Plasma Services Group, a company that has gained a solid reputation as a reliable global supplier of difficult-to-obtain biological raw materials to the life sciences industry, to the Fujirebio group of companies," said Goki Ishikawa, President & CEO of Fujirebio Holdings, Inc.
Enhanced CDMO Capabilities
The acquisition is expected to create synergies between the two companies' offerings in rare samples and biological materials. Ishikawa noted that "current and future IVD and life science partners of Fujirebio and Plasma Services Group will benefit from the synergies in our combined offer of rare samples and biological materials, which in turn further reinforce Fujirebio's position in the market as a trusted CDMO partner."
Nichelle Fernandez, President of Plasma Services Group, emphasized the continuity of the company's mission under the new ownership. "For over 20 years our mission at PSG has always been rooted in serving our customers with care, integrity, and a commitment to quality," she said. "This next chapter with Fujirebio is deeply meaningful. It allows us to stay true to who we are while preserving the personal, responsive service our customers value."
Global Diagnostics Platform Integration
Fujirebio operates as a global R&D-driven company focused on developing new IVD testing technologies and unique biomarkers with high clinical value. The company maintains operations across Japan, Asia, Europe, and the United States, with a mission to create new value in healthcare and contribute to human health and the future of medical care.
The combined organization will leverage Fujirebio's existing CDMO partnerships with leading diagnostic companies worldwide, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions across various platforms.
Fernandez highlighted the potential impact of the partnership: "Together, we're positioned to offer even stronger support for the scientists and innovators who rely on us. Our shared commitment to consistency will have a lasting impact across the global IVD landscape."
The transaction was facilitated by Houlihan Lokey, which served as exclusive financial advisor to Fujirebio, while Achelous Partners acted as exclusive financial advisor to Plasma Services Group.
